Skip to main content
Toggle navigation
Search
Home
Browse by Speaker
Home
Browse by Speaker
Browse by Speaker
Type here to filter the list
All
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
Q
Qiu, Lugui
Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences.
Abstract Session 6
Location: Room 718
Lugui Qiu
(OA-08) Three-Year Follow-Up of FUMANBA-1: a Phase 1b/ 2 Study of Fully Human Anti-BCMA CAR-T Equecabtagene Autoleucel in Patients with Relapsed/Refractory Multiple Myeloma
Location: Room 701
Lugui Qiu
Quach, Hang
St Vincent’s Hospital Melbourne, University of Melbourne, VIC, Australia
(OA-35) TRIgnite- 1Study, Phase 1, First-in-Human Study of ISB 2001: A BCMAxCD38xCD3-Targeting Trispecific Antibody for Patients with Relapsed/Refractory Multiple Myeloma (RRMM)—Dose Escalation (DE) Results
Location: Room 701
Hang Quach
(OA-56) Belantamab for the Treatment of Multiple Myeloma: Results from Part 1 of the First-in-Human Phase 1/2 DREAMM-20 Trial
Location: Room 701
Hang Quach
Round Table discussion
Location: Hall FG
Hang Quach
